1. patients who do not give their consent in writing after informing. 2. being under the age of 18 and over the age of 60. 3. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). 4. volunteers who the researcher thinks may have problems with adherence to treatment. 5. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. 6. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. 7. patients with heart disease or arrhythmia history. 8. patients with gout or hyperuricemia. 9. patients with signs of pneumonia in their lungs. 10. patients with chronic renal failure (glomerular filtration rate \<30). 11. pregnant or breastfeeding patients.

1. patients who do not give their consent in writing after informing. 2. being under the age of 18 and over the age of 60. 3. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). 4. volunteers who the researcher thinks may have problems with adherence to treatment. 5. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. 6. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. 7. patients with heart disease or arrhythmia history. 8. patients with gout or hyperuricemia. 9. patients with signs of pneumonia in their lungs. 10. patients with chronic renal failure (glomerular filtration rate \<30). 11. pregnant or breastfeeding patients.

patients who do not give their consent in writing after informing. being under the age of 18 and over the age of 60. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). volunteers who the researcher thinks may have problems with adherence to treatment. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. patients with heart disease or arrhythmia history. patients with gout or hyperuricemia. patients with signs of pneumonia in their lungs. patients with chronic renal failure (glomerular filtration rate <30). pregnant or breastfeeding patients.

patients who do not give their consent in writing after informing. being under the age of 18 and over the age of 60. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). volunteers who the researcher thinks may have problems with adherence to treatment. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. patients with heart disease or arrhythmia history. patients with gout or hyperuricemia. patients with signs of pneumonia in their lungs. patients with chronic renal failure (glomerular filtration rate <30). pregnant or breastfeeding patients.

1. patients who do not give their consent in writing after informing. 2. being under the age of 18 and over the age of 60. 3. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). 4. volunteers who the researcher thinks may have problems with adherence to treatment. 5. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. 6. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. 7. patients with heart disease or arrhythmia history. 8. patients with gout or hyperuricemia. 9. patients with signs of pneumonia in their lungs. 10. patients with chronic renal failure (glomerular filtration rate <30). 11. pregnant or breastfeeding patients.

1. patients who do not give their consent in writing after informing. 2. being under the age of 18 and over the age of 60. 3. patients with a known history of allergy to one of the study drugs (hydroxychloroquine, favipiravir). 4. volunteers who the researcher thinks may have problems with adherence to treatment. 5. volunteers who will have trouble taking medication by mouth due to resistant nausea, vomiting or chronic diarrhea. 6. patients with chronic liver disease and transaminase (alt or ast) levels 5 times the higher than the normal level. 7. patients with heart disease or arrhythmia history. 8. patients with gout or hyperuricemia. 9. patients with signs of pneumonia in their lungs. 10. patients with chronic renal failure (glomerular filtration rate <30). 11. pregnant or breastfeeding patients.